Suppr超能文献

淋巴结清扫术在肾细胞癌治疗中的作用:系统评价和荟萃分析。

The role of lymph node dissection in the management of renal cell carcinoma: a systematic review and meta-analysis.

机构信息

Department of Urology, Mayo Clinic, Rochester, MN, USA.

Division of Urology, Department of Surgery, University of Toronto, Toronto, Ontario, Canada.

出版信息

BJU Int. 2018 May;121(5):684-698. doi: 10.1111/bju.14127. Epub 2018 Mar 1.

Abstract

Our objective was to evaluate the role of retroperitoneal lymph node dissection (LND) in non-metastatic (M0) and metastatic (M1) renal cell carcinoma (RCC). We searched Medline, EMBASE, Web of Science and Scopus from database inception to 29 August 2017 for studies of patients who underwent partial or radical nephrectomy for M0 or M1 RCC. Two investigators independently selected studies for inclusion. Risk of bias was assessed using the Newcastle-Ottawa scale, Cochrane Collaboration tool and National Heart, Lung and Blood Institute Quality Assessment Tool. Random effects meta-analysis was performed for all-cause-mortality. The GRADE approach was used to characterize quality of evidence. A total of 51 unique studies were included in the qualitative systematic review. Risk of bias was low in 41/51 (80%) studies. LND was not associated with all-cause mortality in either M0 (hazard ratio [HR] 1.02, 95% confidence interval [CI] 0.92-1.12; I = 0%; four studies), M1 (HR 1.04, 95% CI 0.83-1.29; I = 0%; two studies), or pooled M0 and M1 settings (HR 1.00, 95% CI 0.92-1.09; I = 0%; seven studies), with no statistically significant differences according to M stage subgroups (P = 0.50). In the three studies that examined M0 subgroups with a high risk of nodal metastasis, LND was not associated with improved oncological outcomes. Studies on the association of extent of LND with survival reported inconsistent results. Meanwhile, a small proportion of patients with pN1M0 disease demonstrate durable long-term oncological control after surgery, with 10-year cancer-specific survival of 21-31%. Nodal involvement is independently associated with adverse prognosis in both M0 and M1 settings. GRADE quality of evidence was moderate or low for the outcomes examined. Although LND yields independent prognostic information, the existing literature does not support a therapeutic benefit to LND in either M0 or M1 RCC. High-risk M0 patient groups warrant further study, as a subset of patients with isolated nodal metastases experience long-term survival after surgical resection.

摘要

我们的目的是评估腹膜后淋巴结清扫术(LND)在非转移性(M0)和转移性(M1)肾细胞癌(RCC)中的作用。我们检索了 Medline、EMBASE、Web of Science 和 Scopus 从数据库开始到 2017 年 8 月 29 日,以寻找接受部分或根治性肾切除术治疗 M0 或 M1 RCC 的患者的研究。两名调查员独立选择纳入的研究。使用纽卡斯尔-渥太华量表、Cochrane 协作工具和美国国立心肺血液研究所质量评估工具评估偏倚风险。对全因死亡率进行随机效应荟萃分析。使用 GRADE 方法对证据质量进行描述。共有 51 项独特的研究纳入了定性系统评价。41/51(80%)项研究的偏倚风险较低。LND 与 M0(风险比[HR]1.02,95%置信区间[CI]0.92-1.12;I=0%;四项研究)或 M1(HR1.04,95%CI0.83-1.29;I=0%;两项研究)或 M0 和 M1 综合人群(HR1.00,95%CI0.92-1.09;I=0%;七项研究)的全因死亡率均无相关性,且根据 M 期亚组的差异无统计学意义(P=0.50)。在三项检查 M0 亚组淋巴结转移高风险的研究中,LND 与改善肿瘤学结局无关。有关 LND 与生存相关程度的研究报告结果不一致。同时,一小部分 pN1M0 疾病患者手术后表现出持久的长期肿瘤学控制,10 年癌症特异性生存率为 21-31%。淋巴结受累与 M0 和 M1 环境中的不良预后独立相关。检查结果的 GRADE 证据质量为中等到低。尽管 LND 提供了独立的预后信息,但现有文献不支持 LND 在 M0 或 M1 RCC 中具有治疗益处。高危 M0 患者群体需要进一步研究,因为一部分孤立淋巴结转移的患者在手术后可获得长期生存。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验